ArticleBlood2022
Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL.
Open access · hybridAbstract read
In one paragraph
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.2field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- Mapping clinical CAR-T cells: insights from scRNA-seq.Trends in molecular medicine · 2026Review
- Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity.Annals of hematology · 2026Article
- Article
- Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy.Journal for immunotherapy of cancer · 2025Article
- Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.Haematologica · 2025Review
- Severe cytopenia after chimeric antigen receptor-T cell driven by large granular lymphocytes and responsive to steroids.British journal of haematology · 2025Article
- Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management.The Lancet. Haematology · 2024Review
- Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.Annals of laboratory medicine · 2024Review
- Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study).Blood advances · 2024Article
- Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies.International journal of molecular sciences · 2024Review
- Mechanisms and management of CAR T toxicity.Frontiers in oncology · 2024Review
- Recognizing, defining, and managing CAR-T hematologic toxicities.Hematology. American Society of Hematology. Education Program · 2023Review
- Incorporating Immunotherapy with Radiotherapy for Lymphomas.Lymphatics · 2023Article
- Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer.Military Medical Research · 2023Review
- The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.American journal of hematology · 2023Observational
- Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt's Lymphoma.Medical sciences (Basel, Switzerland) · 2023Article
- Review
- Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.Science advances · 2023Article
- The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.Journal of hematology & oncology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Kai RejeskiDepartment of Medicine III, Hematology/Oncology, University Hospital, Ludwig-Maximilians Universität (LMU) Munich, Munich, Germany.ORCID 0000-0003-3905-0251
Zhijie WuHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-3984-0819
Viktoria BlumenbergDepartment of Medicine III, Hematology/Oncology, University Hospital, Ludwig-Maximilians Universität (LMU) Munich, Munich, Germany.ORCID 0000-0003-1379-0876
Wolfgang G KunzDepartment of Radiology, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0002-5021-1952
Susanna MüllerDepartment of Pathology, University Hospital, LMU Munich, Munich, Germany.
Sachiko KajigayaHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Shouguo GaoHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Veit L BückleinDepartment of Medicine III, Hematology/Oncology, University Hospital, Ludwig-Maximilians Universität (LMU) Munich, Munich, Germany.ORCID 0000-0001-7391-7280
Lisa FrölichDepartment of Medicine III, Hematology/Oncology, University Hospital, Ludwig-Maximilians Universität (LMU) Munich, Munich, Germany.
Christian SchmidtDepartment of Medicine III, Hematology/Oncology, University Hospital, Ludwig-Maximilians Universität (LMU) Munich, Munich, Germany.
Michael von Bergwelt-BaildonDepartment of Medicine III, Hematology/Oncology, University Hospital, Ludwig-Maximilians Universität (LMU) Munich, Munich, Germany.
Xingmin FengHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Neal S YoungHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Marion SubkleweDepartment of Medicine III, Hematology/Oncology, University Hospital, Ludwig-Maximilians Universität (LMU) Munich, Munich, Germany.ORCID 0000-0001-9154-9469
German Cancer Research Center · DENational Institutes of Health · USLMU Klinikum · DELudwig-Maximilians-Universität München · DE
Funding
Pathogenesis And Treatment Of Aplastic AnemiaZIAHL002315 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI YOUNG, NEAL S · 2009 to 2025
$60.1MAbstract
PubMed holds no abstract for this paper.
Indexed as
Receptors, Chimeric AntigenAntigens, CD19Bone Marrow Failure DisordersHumansImmunotherapy, AdoptiveReceptors, Antigen, T-CellT-LymphocytesAntigens, CD19Receptors, Antigen, T-CellReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.